245 related articles for article (PubMed ID: 37901249)
21. Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases.
Mahmoudi H; Balighi K; Tavakolpour S; Daneshpazhooh M
Int Immunopharmacol; 2019 Jun; 71():40-42. PubMed ID: 30877872
[TBL] [Abstract][Full Text] [Related]
22. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
[TBL] [Abstract][Full Text] [Related]
23. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A
Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538
[TBL] [Abstract][Full Text] [Related]
24. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Whole-Blood Exchange Transfusion in Refractory Severe Autoimmune Haemolytic Anaemia Secondary to Systemic Lupus Erythematosus: A Real-World Observational Retrospective Study.
Jiang Y; Zhao HJ; Luo H; Li BJ; Zhang ZM; Zhao LD; Zuo XX
Front Immunol; 2022; 13():861719. PubMed ID: 35757744
[TBL] [Abstract][Full Text] [Related]
26. [Pemphigus: a review].
Joly P; Sin C
Ann Dermatol Venereol; 2011 Mar; 138(3):182-200. PubMed ID: 21397148
[TBL] [Abstract][Full Text] [Related]
27. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
28. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells.
Leuci S; Levine D; Zhang J; Razzaque Ahmed A
G Ital Dermatol Venereol; 2009 Aug; 144(4):379-409. PubMed ID: 19755943
[TBL] [Abstract][Full Text] [Related]
29. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
31. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.
Wang HH; Liu CW; Li YC; Huang YC
Acta Derm Venereol; 2015 Nov; 95(8):928-32. PubMed ID: 25881672
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study.
Zhou X; Zhan T; Xu X; Lan T; Hu H; Zhou Y; Xia D; Wang J; Wang Y; Xiao Y; Li W
J Dermatolog Treat; 2024 Dec; 35(1):2302071. PubMed ID: 38247364
[TBL] [Abstract][Full Text] [Related]
34. Pemphigus vulgaris and pemphigus foliaceus: similar prognosis?
Zaraa I; Mokni M; Hsairi M; Boubaker S; Sellami M; Zitouni M; Makni S; Dhahri AB
Int J Dermatol; 2007 Sep; 46(9):923-6. PubMed ID: 17822493
[TBL] [Abstract][Full Text] [Related]
35. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
Tavakolpour S
Int Immunopharmacol; 2017 Dec; 53():133-142. PubMed ID: 29107213
[TBL] [Abstract][Full Text] [Related]
36. Iranian guideline for rituximab therapy in pemphigus patients.
Daneshpazhooh M; Balighi K; Mahmoudi H; Tavakolpour S; Abedini R; Soori T; Ehsani AH; Ghiasi M; Noormohammadpour P; Ghandi N; Lajevardi V; Sadeghinia A; Nasimi M; Azizpour A; Chams-Davatchi C
Dermatol Ther; 2019 Sep; 32(5):e13016. PubMed ID: 31269316
[TBL] [Abstract][Full Text] [Related]
37. Eyelid skin involvement in pemphigus foliaceus.
Daoud YJ; Foster CS; Ahmed R
Ocul Immunol Inflamm; 2005; 13(5):389-94. PubMed ID: 16419424
[TBL] [Abstract][Full Text] [Related]
38. [Transition from pemphigus vulgaris to pemphigus foliaceus: a case report].
Lévy-Sitbon C; Reguiaï Z; Durlach A; Goeldel AL; Grange F; Bernard P
Ann Dermatol Venereol; 2013 Dec; 140(12):788-92. PubMed ID: 24315225
[TBL] [Abstract][Full Text] [Related]
39. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
40. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
